KRAS and neoplasm: Finally, while it is apparent that disrupting KRAS–PDEδ interactions is a viable approach to inhibiting mutant KRAS-driven tumor cell growth, it is also apparent that additional compounds with greater target selectivity, as well as lower cytotoxicity and higher binding affinity, need to be identified.